Company

Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Lempo Therapeutics

Main focus: Gene editing-based treatments for attenuating chronic disease

Company stage: Pre-clinical

Diseases (gene editing): Pulmonary Arterial Hypertension, PAH

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: Binyamina, Israel

Website: https://www.lempo-tx.com/

Pipeline: https://www.lempo-tx.com/

Lempo Therapeutics is an Israel-based, pre-clinical gene editing company, utilising CRISPR-Cas9 to edit stem-cells ex vivo, to inactivate disease causing myeloperoxidase (MPO) proteins in patients suffering from pulmonary arterial hypertension. Using CRISPR, Lempo edits CD34⁺ cells to knock out the MPO gene, after which the cells can be reinfused into patients.

Lempo Therapeutics

Your Latest CMN News

CMN Weekly (19 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

A Secondary Checkpoint Refines CRISPR Precision

New findings highlight a secondary conformational checkpoint in CRISPR-Cas9 that significantly enhances its accuracy in gene editing.

Cancer's Weak Point Is Its Metabolism, CRISPR...

American researchers have developed a novel CRISPR-based platform to identify and characterise essential nutrient transporters that support cancer...

Next-Generation CRISPR Screening Libraries Without...

Sponsored content

Founded in 2018, Vivlion is a spin-out of Goethe University Frankfurt. Its mission is to provide innovative gene-editing reagents and screening...

CMN Weekly (12 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

Scientists use CRISPR to develop new detection...

Scientists in China describe a sensitive and selective CRISPR-Cas12-based assay for the detection of a protein that is implicated in obesity and...

Company: Lempo Therapeutics

Search CRISPR Medicine